Cleveland Clinic Testing Out Breast Cancer Vaccine



Source: Adobe Stock
Approximately one in eight women will be diagnosed with breast cancer at some point in their lives and according to the TODAY show, some of those women will be diagnosed with triple-negative breast cancer – an aggressive form of the disease.
However, researchers at the Cleveland Clinic are testing out a vaccine that will hopefully prevent breast cancer in the future, although it could take decades to implement if tests prove successful.
According to TODAY, the phase 1 clinical trial for the vaccine targets a protein called alpha-lactalbumin, which is usually made in lactating breasts. TODAY reports that the body does not make this protein at any other time except in some 70 percent of triple-negative breast cancers. “What we hope to do is, first, show that we can mount an immune response against one protein that is expressed in the majority of triple-negative breast cancer,” Cleveland Clinic oncologist Dr. G. Thomas Budd told TODAY. “And if we can, we might be able to vaccinate patients or people who are at risk to develop breast cancer, and then prevent them from getting it in the first place — that’s the long-term goal.”
“The ultimate goal, ultimately, not of this trial, but future trials, would be to be able to prevent breast cancer, triple-negative breast cancer in those who are at very high risk for it,” Dr. Budd continued. “So, initially this would be people with family histories and genetic mutations known to predispose them to triple-negative breast cancer.”
TODAY reports triple-negative breast cancer accounts for approximately 10 to 15 percent of all breast cancers and is most commonly found in women under 40, black women, and women who have the BRCA1 mutation.
“I think the main thing I do want to just emphasize is this is very, very early in development,” Dr. Budd cautioned. “It will take really decades to prove what we need to prove because it takes years to develop breast cancer, but you know it’s the first step.”